Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm the benefit. Adding a second immunotherapeutic agent to a PD-1 inhibitor failed to slow disease progression or improve survival in patients with unresectable or metastatic melanoma.
Learn more by clicking here.
Immunotherapy Combo Fails Melanoma Test
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm the benefit. Adding a second immunotherapeutic agent to a PD-1 inhibitor failed to slow disease progression or improve survival in patients with unresectable or metastatic melanoma.
Learn more by clicking here.
